Reading Time: 7 minutes On 25th April 2023 Tofersen (now known as Qalsody in the US), a treatment for SOD1 MND was approved by the Food and Drug Administration
Category: Clinical Trials
Reading Time: 5 minutes Last year was a really exciting year for MND clinical trials, with more trials recruiting in the UK than ever before, some promising results being
Reading Time: 4 minutes Last year was a really exciting year for MND clinical trials, with more trials recruiting in the UK than ever before, some promising results being
Reading Time: 3 minutes When you think of scientific research most people will immediately imagine a laboratory with scientists in white lab coats, however MND research takes many forms. As well as research that looks for effective treatments, it is also important to investigate ways to improve the well-being of people living with MND and their carers/family members.
Reading Time: 6 minutes It has been suggested that there might be a pre-symptomatic stage of MND, where the disease is active and occurring within a person but no symptoms are showing. There is currently little research in this area and a lack of evidence of a pre-symptomatic stage of the disease. However, if it can be shown that there is a pre-symptomatic stage which can be measured, this could be very useful in helping people with MND to get treatment as early as possible. Dr Michael Benatar, from the University of Miami, has been looking into this by studying the development of MND and how the disease presents in people who have a high risk of developing it.
Reading Time: 5 minutes What is a clinical endpoint?
A clinical endpoint is used to determine if the drug that is being tested in a clinical trial is beneficial to the people it is intended to treat – those effects that directly measure how a participant in the trial feels, functions or survives.
To determine a clinical endpoint, it is important to understand how a person with a disease feels and functions, and this is well understood in MND. So, a drug that improves any of these could be seen to be beneficial.
Reading Time: 6 minutes Over the last year ALS/MND clinical trials have taken centre stage, with more trials than ever opening for recruitment in the UK, the news of promising results from some trials and the approval of drugs by some regulatory authorities. With the year coming to an end, we thought we would roundup some recent clinical trial updates that were presented at the 33rd International Symposium on ALS/MND.
Reading Time: 5 minutes The top-line results of the Modifying Immune Response and OutComes in ALS (MIROCALS) clinical trial were announced on 6 December 2022 at the 33rd International Symposium
Reading Time: 2 minutes This blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type correspond
Reading Time: 5 minutes This blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type